EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Patient- and clinician-reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study

Jose Luis López Estebaranz iD, Anthony Bewley iD, Andreas Pinter iD, Jordi Galván iD, Volker Koscielny

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag185 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Jose Luis López Estebaranz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Hauptthemen laut MEDLINE: Betamethasone, Psoriasis, Scalp Dermatoses, Calcitriol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Almirall S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The novel cream formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion technology (CAL/BDP PAD-cream) has shown promising results on psoriasis in phase III clinical trials. However, real-world data on scalp psoriasis are limited.

Objectives

To assess clinician-reported outcomes (ClinROs) and patient-reported outcomes (PROs) of CAL/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis under real-world conditions in Europe.

Methods

PRO-SCALP is a prospective, noninterventional, multicentre, cohort study conducted between June 2023 and October 2024 in Germany, Spain and the UK. Data were collected at baseline and week 8 (end of study, EOS). PROs included the Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep disturbances, the Psychosocial Effects of Scalp Psoriasis Questionnaire and adherence. ClinROs included treatment satisfaction, Physician’s Global Assessment of scalp (scalp-PGA) and scalp-modified Psoriasis Area and Severity Index (S-mPASI). The trial was registered at ClinicalTrials.gov (NCT05811234).

Results

In total, 253 patients had evaluable data (mean age 47.9 years; 65.2% female). Of them, 59.9% reported high adherence (visual analogue scale score 80–100). At EOS, the mean (SD) global satisfaction (TSQM-9) was 76.0 (21.6) and 77.6% of patients achieved a scalp-PGA score of 0/1 (clear/almost clear). Moreover, 68.4% achieved scalp-PGA success (scores of 0/1 and ≥ 2-point improvement). WI-NRS, S-mPASI and Scalpdex scores improved significantly (P < 0.001) from baseline to EOS. Sleep patterns and psychosocial outcomes also improved.

Conclusions

CAL/BDP PAD-cream is associated with high treatment satisfaction and improved clinical outcomes and quality of life in the real-world management of scalp psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BetamethasonePsoriasisScalp DermatosesCalcitriolDermatologic AgentsHumansProspective StudiesFemaleMaleAdultMiddle AgedDrug CombinationsPatient SatisfactionPatient Reported Outcome MeasuresTreatment OutcomeSeverity of Illness IndexSkin CreamQuality of Life

Substanzen

BetamethasoneCalcitriolDrug CombinationsDermatologic Agentsbetamethasone-17,21-dipropionatecalcipotrienebetamethasone dipropionate, calcipotriol drug combination

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Department of Dermatology, Barts Health NHS Trust & Queen Mary University, London, UK.
  • Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
  • Global Medical Affairs Department, Almirall S.A., Barcelona, Spain.

ORCID-Profile: Jose Luis López Estebaranz, Anthony Bewley, Andreas Pinter, Jordi Galván

Förderung

  • Almirall S.A.

Zitieren

APA

López Estebaranz, J. L., Bewley, A., Pinter, A., Galván, J., & Koscielny, V. (2026). Patient- and clinician-reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag185

Vancouver

López Estebaranz JL, Bewley A, Pinter A, Galván J, Koscielny V. Patient- and clinician-reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag185

BibTeX
@article{LpezEstebaranz2026,
  author = {López Estebaranz, Jose Luis and Bewley, Anthony and Pinter, Andreas and Galván, Jordi and Koscielny, Volker},
  title = {Patient- and clinician-reported outcomes of calcipotriol/betamethasone dipropionate PAD-cream for the treatment of adult patients with scalp psoriasis under real-world conditions: results from the prospective, noninterventional, multicentre PRO-SCALP study},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag185}
}
Kostenlos starten →